|
|
 |
|
Viewing report
|
|
|
|
Targeted Drug Delivery Analysis
Espicom Business Intelligence Ltd, July 2009
With drug delivery taking a more important role in the drug development and generic industries, business planners, marketers and commercial executives must know the developments which could influence their decisions. In such a competitive and challenging marketplace, the need to stay in touch with the latest corporate twists and turns grows ever greater.
Finding precisely that information quickly and easily in a world suffering from information overload is no easy task. That is why Targeted Drug Delivery Analysis is the time-saving choice of busy executives - no longer will you have to waste time searching through many and varied sources and publications to keep up-to-date.
Combining data from Espicom’s leading drug delivery information services and reports, this service provides a regularly-updated view of the companies, products, research and players - all in one convenient and easy-to-use online service.
Best of all, this valuable resource can be shared with colleagues throughout your organisation with our cost-effective and flexible distribution packages.
This unique business information service provides answers to key industry questions such as...
- By 2018, 19 companies are expected to have new or improved targeted drug delivery products in the market - who are they?
- What is the status of key therapeutic agents such as liposomes, PEGylation and radioimmunoconjugates?
- Which strategies are proving most productive and for which companies?
- What are the prospects for Immunogen’s TAP technology by 2018?
- What will the product/company landscape look like in 2018?
- What are the latest deals and licences on the horizon?
- What are the relative strengths and weaknesses of research pipelines?
Are you...
- Monitoring the competitive landscape of companies developing targeted drug delivery technology?
- Looking for strategic partners and collaborators and need to review prospective customers?
- Tracking developments in specific targeted technologies and need to stay abreast of the changes?
This service provides...
- Regularly updated news
- Company watch
- Technology/company analysis & futures
- Immediate access to all data via a fast and easy-to-use web interface
An essential business intelligence resource providing full coverage of companies, technologies, products and prospects active in the targeted drug delivery sector
By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8.5 billion.
Despite considerable advances in drug delivery technologies, there continues to be a high unmet clinical need for safer and better-tolerated drugs. Sub-optimal compliance and failure to persist with drug treatments are important determinants of therapeutic non-response and are of significant cost to healthcare providers. Advanced targeted drug delivery technologies will help to overcome some of these issues by improving pharmacokinetics, increasing tolerability and reducing dose-limiting off-target effects.
The need for targeted delivery platforms is increasing as patients and drug regulators seek to meet these challenges.
Current and future applications
Whilst the majority of targeted delivery systems under evaluation incorporate passive carrier systems, there will be a shift towards the use of actively targeted carriers to increase the therapeutic index of existing and new products.
There are significant opportunities for future commercial developments within the pharmaceutical industry. These include:
- Cost-effective production of antibodies and antibody fragments for drug targeting;
- Development of new polymers and biopolymers that may be utilised in the safe and efficient targeted delivery of drugs and pro-drugs into host cells;
- Development and selective targeting of macromolecules to improve intracellular uptake and tissue specificity;
- Development of inactive pro-drugs for tissue specific release;
- Extended product lifecycles through the development of targeted formulations;
- Identification of new targeting ligands to improve the targeted delivery of small molecules and macromolecules;
- Utilisation of multiple targeting ligands to address the needs of patient sub-types; and,
- Combined technology platforms to develop targeted therapeutics and diagnostics in a single molecule.
A new generation of targeted delivery systems is under development to meet these needs which should provide greater control over the selective targeting of tissue, either with active moieties or inactive moieties which may be activated within the tissue by biological (enzymes), chemical (pH) or physical means (light, ultrasound) in order to release the active agent. The multitude of delivery platforms will lend themselves to the delivery of both small molecules and macromolecules and to a variety of target sites and delivery routes.
Saving you time, money and research effort...
1. Daily-Updated Targeted Drug Release News
The latest corporate developments from the world of targeted drug release covering deals, strategic alliances, mergers/acquisitions, company performance and research.
2. Monthly-Updated Company Watch
Review developments in the context of a company’s operation and competitive position. Companies are tracked daily and updated online each month.
Content for each company
- Overview & Technology Focus
- Key Personnel
- Key Milestones
- Competition & Competing Products
- Products/Technologies
- R&D & Research Strategy
- Key Agreements & Alliances
- Financial Data (where available)
- Comprehensive Contact Details
3. Technology/Corporate Analysis & Futures
The data provided in this section was first published in June 2009 as part of a report called Drug Delivery Technologies: Players, products and prospects to 2018. Its inclusion in this service allows the information to be viewed in context of market developments as they progress.
Overview of delivery technologies for targeted delivery: past, present & future
Systemic targeted delivery: motivators & resistors
TARGETED DELIVERY TECHNOLOGIES
Types of systemic targeted delivery platforms in development in the pharma industry
Targeting ligands
- Antibody fragment conjugate delivery
- Antibody-directed enzyme pro-drug targeted delivery
- Peptide-induced release for targeted delivery
- Small molecule conjugate delivery
- Nucleomic-mediated targeted intranuclear delivery
- Cobalamin-mediated targeted intracellular delivery
Non-biological targeting platforms
- Magnetically and Photosensitive targeted delivery
Current therapeutic applications for targeted delivery
Leading systemic targeted products in development
Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
- Leading targeted drug delivery companies
- Strategic partnerships & acquisitions
- Intellectual property
THE TARGETED DELIVERY MARKET
- Now: Approved targeted delivery product sales
- Future 2018: Global targeted-release product sales and novel targeted delivery product sales
COMPETITOR ANALYSIS
- Detailed analysis of leading companies covering:
- Proprietary delivery technology
- Applications in the pharmaceutical industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products utilising the delivery technology
- Competitor ratio analysis
Customers who bought this item also bought
Nanotechnology: Players, products & prospects to 2018 (Volume II)
Nanoparticle Drug Delivery Market Report
Drug Solubility Technology and Platforms: Evolving Strategies, Emerging Opportunities
Controlled-release: Players, products & prospects to 2018 (Volume I)
The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
Competitor Analysis: Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease
Drug Delivery Systems: US Market Outlook, Advances for Pharma, Biotech & Medical Devices
Nitric Oxide - Therapeutics, Markets and Companies
Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
|
|
|
|
